“It’s not simply about just growing your earnings per share by raising your prices,” Regeneron Pharmaceuticals Cofounder Leonard Schleifer tells Forbes.
Schleifer has an axe to grind with the current drug pricing practices by pharmaceutical companies in the U.S., and says he’s taking active steps to set an example in the industry by offering lower-than-usual prices typically expected from pharma.
When working to find a fair price for Dupixent and a cholesterol treatment, Schleifer told Forbes Regeneron submitted the drug for an external review.
“These were unprecedented steps that set a shining example of how it is possible to make great medical advances and provide those advances at a fair price,” he said.
To read the full article on Forbes, click here.
